Details of the Drug Combination

General Information of Drug Combination (ID: DCPR2ZA)

Drug Combination Name
Ceftriaxone Levofloxacin
Indication
Disease Entry Status REF
Cholangitis Phase 4 [1]
Component Drugs Ceftriaxone   DMCEW64 Levofloxacin   DMS60RB
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ceftriaxone
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [2]
Bacteremia 1A73 Approved [2]
Bacterial arthritis N.A. Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Chancroid N.A. Approved [2]
Endometritis N.A. Approved [2]
Escherichia coli meningitis N.A. Approved [2]
Gonococcal infection of joint N.A. Approved [2]
Meningococcal meningitis N.A. Approved [2]
Pneumococcal meningitis N.A. Approved [2]
Staphylococcal pneumonia N.A. Approved [2]
Pelvic inflammatory disease GA05 Investigative [2]
Ceftriaxone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Modulator [6]
------------------------------------------------------------------------------------
Ceftriaxone Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [7]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [8]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Ceftriaxone Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-lactamase (blaB) DEEAL81 BLA2_KLEPO Metabolism [10]
Beta-lactamase (blaB) DEYIEO5 AMPC_SERMA Metabolism [11]
Beta-lactamase (blaB) DEBKS91 A0A1B1FBM9_ACIBA Metabolism [12]
------------------------------------------------------------------------------------
Ceftriaxone Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Dihydrofolate reductase (DHFR) OT3DVIGM DYR_HUMAN Decreases Activity [13]
------------------------------------------------------------------------------------
Indication(s) of Levofloxacin
Disease Entry ICD 11 Status REF
Acute maxillary sinusitis N.A. Approved [4]
Anthrax 1B97 Approved [4]
Bacterial infection 1A00-1C4Z Approved [5]
Latent tuberculosis infection N.A. Approved [4]
Mycoplasma pneumoniae pneumonia N.A. Approved [4]
Pyelonephritis N.A. Approved [4]
Staphylococcal pneumonia N.A. Approved [4]
Staphylococcus aureus infection N.A. Approved [4]
Streptococcal pneumonia N.A. Approved [4]
Pneumonia caused by chlamydia N.A. Investigative [4]
Levofloxacin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [6]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [6]
------------------------------------------------------------------------------------
Levofloxacin Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [14]
------------------------------------------------------------------------------------
Levofloxacin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-lactamase (blaB) DEP0IWS A0A378EHS6_KLEPR Metabolism [15]
------------------------------------------------------------------------------------
Levofloxacin Interacts with 11 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Dihydrofolate reductase (DHFR) OT3DVIGM DYR_HUMAN Decreases Activity [13]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Increases Expression [16]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Decreases Expression [16]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [16]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Decreases Expression [16]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [16]
Tumor necrosis factor-inducible gene 6 protein (TNFAIP6) OT1SLUZH TSG6_HUMAN Decreases Expression [16]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Increases Expression [16]
PTB-containing, cubilin and LRP1-interacting protein (PID1) OT5YJ7FI PCLI1_HUMAN Decreases Expression [16]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) OTUYHB84 MLP3B_HUMAN Increases Expression [17]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Increases Expression [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DOT(s)

References

1 ClinicalTrials.gov (NCT03087656) Antibiotics to Decrease Post ERCP Cholangitis
2 Ceftriaxone FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5326).
4 Levofloxacin FDA Label
5 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
8 Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
9 Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95.
10 Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother. 1996 Sep;38(3):409-24.
11 Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.
12 Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5.
13 Investigation of the effects of some drugs and phenolic compounds on human dihydrofolate reductase activity. J Biochem Mol Toxicol. 2015 Mar;29(3):135-9.
14 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
15 Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
16 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
17 TNF enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17.